Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)

This “allocated fund in clinical research” was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years.

News & Events

Posted on

Delighted to announce the upcoming workshop “Organoids in Cancer Research workshop” in person (COVID-safe) on 24 Nov., 2021 at the AGORA Cancer…

Read more
Posted on

Once again, the SUR-SRP “Summer Research” program (July 5 to August 27), organized by the UNIL and the EPFL and supported by the ISREC Foundation, was…

Read more
Posted on

The ISREC Foundation is proud to support the work of Prof. Johanna Joyce and her team, who have developed a comprehensive and integrated toolkit for a…

Read more
Posted on

Congratulations to Prof. Denis Migliorini, holder of the ISREC Foundation Immuno-Oncology Chair. Together with Prof. Andrea Alimonti, he has been…

Read more